Company profile: Lexeo Therapeutics
1.1 - Company Overview
Company description
- Provider of gene therapy candidates for genetically defined cardiovascular and CNS diseases, including LX2006 for cardiac Friedreich’s ataxia (frataxin), LX2020 for arrhythmogenic cardiomyopathy (PKP2), LX2021 for desmoplakin cardiomyopathy and certain forms of dilated cardiomyopathy (connexin 43), LX2022 for hypertrophic cardiomyopathy (TNNI3), and CNS APOE2 programs for APOE4 homozygous Alzheimer’s (LX1001, LX1020).
Products and services
- LX1001: A CNS-directed gene therapy constructs APOE2 expression in APOE4 homozygous patients’ CNS to slow Alzheimer’s progression by restoring protective APOE2 protein levels
- LX1020: A CNS-directed gene therapy expresses protective APOE2 in the CNS of APOE4 homozygous patients while co-delivering miRNA to suppress pathogenic APOE4 protein expression
- LX2006: A cardiac-targeted gene therapy delivers a functional frataxin gene to myocardial cells to restore normal mitochondrial function, addressing Cardiac Friedreich’s Ataxia pathophysiology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lexeo Therapeutics
Cenes
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical products, developing and commercializing drugs for pain control, sedation, and other central nervous system disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cenes company profile →
Sania Therapeutics
HQ: United Kingdom
Website
- Description: Provider of precision genetic neuromodulation therapies for nervous system disorders, using chemogenetics to safely and accurately alter neuronal activity and stabilize faulty electrical signaling. Offers AAV-based delivery systems with proprietary human-centric platforms to target specific cells. Lead program addresses hyperexcitable motor dysfunctions, such as spasticity, by targeting neural subtypes for long-term therapeutic benefit.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sania Therapeutics company profile →
Jazz Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals for underserved neurology and psychiatry markets. Includes Xyrem and Xywav for cataplexy and excessive daytime sleepiness in narcolepsy; Epidiolex for seizures in Lennox-Gastaut syndrome, Dravet syndrome, or Tuberous Sclerosis Complex; Vyxeos for acute myeloid leukemia; Zepzelca for metastatic small cell lung cancer; Defitelio for hepatic veno-occlusive disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jazz Pharmaceuticals company profile →
Knopp Biosciences
HQ: United States
Website
- Description: Provider of clinical-stage small-molecule treatments, including dexpramipexole for eosinophilic asthma and a Kv7 platform for epilepsy and other hyperexcitability disorders; engaged in drug discovery and development for neurological disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Knopp Biosciences company profile →
Engrail
HQ: United States
Website
- Description: Provider of medicines for patients with life-limiting diseases of the nervous system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Engrail company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lexeo Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lexeo Therapeutics
2.2 - Growth funds investing in similar companies to Lexeo Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lexeo Therapeutics
4.2 - Public trading comparable groups for Lexeo Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →